Triple Hormone-Receptor Assay: A More Accurate Predictive Tool for the Treatment of Advanced Breast Cancer?

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.1979.277
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Estrogen Receptor-Beta Is a Potential Target for Triple Negative Breast Cancer Treatment

Oncotarget
Oncology
2018English

Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Clinical Medicine Insights: Oncology
Oncology
2015English

Hormone Receptor-Negative as a Predictive Factor for Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer

Einstein (São Paulo, Brazil)
Medicine
2019English

Targeting MYC for Triple-Negative Breast Cancer Treatment

Oncoscience
Cancer ResearchOncology
2018English

Androgen Receptor-Positive, Triple-Negative Breast Cancer

Cancer
Cancer ResearchOncology
2017English

A Multigene Predictor of Metastatic Outcome in Early Stage Hormone Receptor-Negative and Triple-Negative Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2010English

Cetuximab-Conjugates Nanoparticles for the Treatment of Triple Negative Breast Cancer

2019English

Platinum-Based Therapy for Triple-Negative Breast Cancer Treatment: A Meta-Analysis

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy